



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Sparsentan

Item No. 33429

**CAS Registry No.:** 254740-64-2  
**Formal Name:** 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide  
**MF:** C<sub>32</sub>H<sub>40</sub>N<sub>4</sub>O<sub>5</sub>S  
**FW:** 592.8  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Sparsentan is supplied as a crystalline solid. A stock solution may be made by dissolving the sparsentan in the solvent of choice, which should be purged with an inert gas. Sparsentan is soluble in the organic solvent DMSO.

### Description

Sparsentan is a dual antagonist of angiotensin II type 1 (AT<sub>1</sub>) and endothelin receptor type A (ET<sub>A</sub>; K<sub>i</sub>s = 0.8 and 9.3 nM, respectively, for the human receptors).<sup>1</sup> It is selective for these receptors over AT<sub>2</sub> and ET<sub>B</sub> receptors (K<sub>i</sub>s = >10 μM for both). Sparsentan inhibits angiotensin II-induced pressor responses in conscious normotensive rats (ED<sub>50</sub> = 3.6 μmol/kg, p.o). It reduces mean arterial pressure in spontaneously hypertensive rats when administered orally at doses of 10, 30, or 100 μmol/kg per day. Dietary administration of sparsentan (1,800 ppm) reduces albuminuria and inhibits development of glomerulosclerosis in the gddY mouse model of IgA nephropathy.<sup>2</sup>

### References

1. Murugesan, N., Gu, Z., Fadnis, L., *et al.* Dual angiotensin II and endothelin A receptor antagonists: Synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. *J. Med. Chem.* **48(1)**, 171-179 (2005).
2. Nagasawa, H., Suzuki, H., Jenkinson, C., *et al.* The dual endothelin ETA and angiotensin AT1 receptor blocker sparsentan protects against the development of albuminuria and glomerulosclerosis in the gddY mouse model of IgA. *Nephrol. Dial. Transplant.* **35(Suppl. 3)**, P0348 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/08/2021

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM